Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
EDINBURGH, United Kingdom, Nov. 20, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
-
EDINBURGH, United Kingdom, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
-
NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer
NuTide:302 Study Will Evaluate NUC-3373 in Combination with Other Agents Typically Administered with 5-FU EDINBURGH, United Kingdom, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA)...
-
Single-Agent Anti-Cancer Activity Observed in Patients with Advanced Solid Tumors NUC-3373 Demonstrates Potential Advantages Compared to 5-FU NuCana has Initiated a Phase Ib Study of NUC-3373 in...
-
50% Objective Response Rate on Intent-to-Treat Basis Observed Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer Planned EDINBURGH, United Kingdom, Oct. 21, 2018 (GLOBE...
-
EDINBURGH, United Kingdom, Oct. 09, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
-
EDINBURGH, United Kingdom, Aug. 29, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
-
EDINBURGH, United Kingdom, Aug. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2018 and provided an update on its extensive...
-
EDINBURGH, United Kingdom, May 25, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
-
EDINBURGH, United Kingdom, May 23, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...